Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia - PubMed
5 hours ago
- #Fracture Risk
- #Iron Deficiency Anemia
- #Bone Formation
- Ferric carboxymaltose (FCM) increases fracture risk and reduces bone formation in patients with iron deficiency anemia (IDA).
- FCM causes hypophosphatemia in most patients, leading to osteomalacia and fractures, unlike ferric derisomaltose (FDI).
- A study of 357 patients and over 20,000 from the TriNetX database showed higher fracture rates with FCM compared to FDI.
- Mouse models revealed FCM lowers collagen and ossification gene expression and increases bone iron concentrations.
- FCM inhibits binding of dentin matrix protein 1 to αVβ3-integrin on osteocytes, reducing bone formation.
- FCM treatment in IDA directly impairs bone formation and increases fracture risk.